Wall Street brokerages expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to announce ($0.27) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for TRACON Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.19). TRACON Pharmaceuticals reported earnings per share of $0.07 during the same quarter last year, which suggests a negative year over year growth rate of 485.7%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that TRACON Pharmaceuticals will report full year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to ($1.08). For the next year, analysts anticipate that the company will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.42) to ($0.27). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow TRACON Pharmaceuticals.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02).
Shares of TCON remained flat at $$2.25 during midday trading on Friday. The company’s stock had a trading volume of 138,299 shares, compared to its average volume of 99,231. TRACON Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $3.95. The firm has a market cap of $65.65 million, a P/E ratio of -1.97 and a beta of 1.87. The company has a debt-to-equity ratio of 0.17, a current ratio of 4.84 and a quick ratio of 4.84.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its holdings in shares of TRACON Pharmaceuticals by 368.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 76,999 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 60,574 shares in the last quarter. Alambic Investment Management L.P. bought a new position in shares of TRACON Pharmaceuticals in the 1st quarter valued at about $213,000. Renaissance Technologies LLC grew its holdings in shares of TRACON Pharmaceuticals by 40.7% in the 2nd quarter. Renaissance Technologies LLC now owns 719,900 shares of the biopharmaceutical company’s stock valued at $1,944,000 after acquiring an additional 208,300 shares in the last quarter. Finally, NEA Management Company LLC grew its holdings in shares of TRACON Pharmaceuticals by 25.7% in the 1st quarter. NEA Management Company LLC now owns 3,467,181 shares of the biopharmaceutical company’s stock valued at $7,975,000 after acquiring an additional 707,964 shares in the last quarter. Institutional investors own 56.40% of the company’s stock.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.